Loading...
XSHG
688389
, Last price  
Name

Shenzhen Lifotronic Technology Co Ltd

Chart & performance

D1W1MN
XSHG:688389 chart
P/E
—
P/S
—
EPS
0.43
Vol. 1Y
—
Shs. 5Y
0.44%
Rev. 5Y
13.38%
Div Yld LY
—
Div Yld TTM
—
Revenues
1.04b
-9.60%
174,536,239250,829,742323,429,252422,644,271553,823,039778,107,053983,044,7501,145,718,8251,148,037,7991,037,830,999
Net income
186m
-46.12%
10,384,26756,424,95581,144,022100,559,718143,948,223190,347,066251,482,903328,579,955345,391,541186,094,700
CFO
281m
-5.23%
27,999,80335,252,00081,143,09391,824,906136,415,561182,066,248271,711,959303,823,443296,470,545280,965,580
Dividend
May 28, 20260.282 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2008 and headquartered in Shenzhen, China, Shenzhen Lifotronic Technology Co., Ltd. specializes in the design, production, and distribution of a wide range of medical devices throughout China, addressing both diagnostic and therapeutic requirements. Its extensive portfolio includes In Vitro Diagnostic (IVD) products, featuring sophisticated analytical instruments such as HPLC systems for hemoglobin and HbA1c measurements, automated ECL immunoassay analyzers, and hematology analyzers. The company also provides Point-of-Care Testing (POCT) solutions, including immunofluorescence analyzers, alongside molecular diagnostics equipment like automated nucleic acid purification systems and real-time PCR platforms. Additionally, Lifotronic offers rapid test kits for key infectious diseases such as COVID-19, malaria, dengue, and influenza A and B. In the therapeutic sector, the company delivers a diverse array of solutions. Respiratory and ICU products encompass video laryngoscopes, warmer units with disposable blankets, high-flow humidification systems, high-frequency chest wall oscillation devices, and intermittent pneumatic compression pumps. For wound care, offerings include negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy. Pain management is addressed through ESWT (Extracorporeal Shockwave Therapy) devices, specifically electromagnetic and extracorporeal shockwave systems. Furthermore, Lifotronic is active in medical and aesthetic laser technologies, providing intensive pulsed light systems, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems.
IPO date
Nov 05, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT